Equity Overview
Price & Market Data
Price: $38.58
Daily Change: +$1.14 / 2.95%
Range: $34.00 - $38.68
Market Cap: $7,172,523,520
Volume: 1,658,057
Performance Metrics
1 Week: 6.57%
1 Month: 0.34%
3 Months: -6.22%
6 Months: -19.20%
1 Year: 5.90%
YTD: -11.80%
Company Details
Employees: 534
Sector: Health technology
Industry: Pharmaceuticals: other
Country: United States
Details
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291), and zoldonrasib G12D (RMC-9805), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C). The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; RMC-5552, a selective inhibitor of mTORC1 signaling in tumors, which is in phase 1 clinical trial; and RMC-5845 that targets SOS1. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.